
    
      This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center
      non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of
      KSI-301 5 mg in participants with treatment-na√Øve DME.

      The primary endpoint will be assessed at Year 1; additional secondary endpoints for efficacy
      will be assessed at Years 1 and 2.
    
  